Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-up Study of CBL-514 for Reducing Abdominal Subcutaneous Fat
NCT07733947Phase 3Not yet recruiting
- Sponsor
- Caliway Biopharmaceuticals
- Start
- Dec 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 3 trial of CBL-514 in abdominal subcutaneous fat, sponsored by Caliway Biopharmaceuticals. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
CBL-514
03
Conditions
abdominal subcutaneous fat
Beyond the preview
Go deeper on NCT07733947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07733947.